US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

As for­mer Pres­i­dent Don­ald Trump like­ly re­turns to pow­er — the As­so­ci­at­ed Press pro­ject­ed his pres­i­den­tial vic­to­ry Wednes­day morn­ing — the bio­phar­ma in­dus­try may see the door … ...

Aca­dia Phar­ma­ceu­ti­cals has sold its pri­or­i­ty re­view vouch­er for $150 mil­lion, the com­pa­ny said Tues­day, but did not dis­close the buy­er … ...

Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions of ADHD medications and other ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Gilead and Ar­cel­lx’s ear­ly tri­al da­ta on their mul­ti­ple myelo­ma cell ther­a­py show that pa­tients saw no cas­es of ...